Recombinant Anti-PD-L1 antibody [28-8]

SKU: N/A Categories: , ,

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [28-8] to PD-L1
  • Suitable for: ICC/IF, IHC-P, WB, Flow Cyt, IHC-Fr
  • Knockout validated
  • Reacts with: Human, Recombinant fragment

Overview

Product name

Anti-PD-L1 antibody [28-8]
See all PD-L1 primary antibodies

Description

Rabbit monoclonal [28-8] to PD-L1

Host species

Rabbit

Tested applications

Suitable for: ICC/IFIHC-PWBFlow CytIHC-Frmore details

Species reactivity

Reacts with: Human, Recombinant fragment

Immunogen

Recombinant full length protein corresponding to Human PD-L1 (extracellular). The immunogen contains the specific extracellular domain of huPD-L1 (Phe19-Thr239). See reference for more info – www.ncbi.nlm.nih.gov/pmc/articles/PMC4561627/
Database link: Q9NZQ7

Positive control

  • Tissue: Human tonsil, head and neck squamous cell carcinoma and placenta tissues; L2987 cell line. Cell Lines: Positives: B-CPAP (high), ES-2 (medium), HCC70 (low), CHO-PDL1, U-87 MG For additional information – please refer to this publication: Programmed death-ligand 1 (PD-L1) expression in various tumor types – http://www.immunotherapyofcancer.org/content/1/S1/P53 IHC-Fr: Frozen human tonsil tissue sections

General notes

FURTHER INFORMATION ON POSITIVE CONTROLS (Chinese version)

Tissue:
– Tonsil – with hyperreactive changes. Screening of hyper-reactive tonsils is recommended to find tonsil with the highest expression of PD-L1 in crypt epithelium, macrophages homing the germinal centers and interfollicular mononuclear leukocytes.
– Tumor tissues – prescreened for positive tumor and inflammatory infiltrates. PD-L1 expression varies by tumor type so screening is recommended to find positive and negative tumor controls.
– The following publication is useful for finding suitable tumor types for PD-L1 expression: 
http://www.immunotherapyofcancer.org/content/1/S1/P53
– Note: Look for specimens with high numbers of inflammatory macrophages and mononuclear leukocytes.

Cell Lines:
– Positive controls: B-CPAP (high), ES-2 (medium), HCC70 (low).

Primary antibody negative control: Recombinant Rabbit IgG isotype control antibody, ab172730.

Recombinant protein positive control: Recombinant human PD-L1 protein, ab167713.

Immunohistochemistry usage:
For IHC usage on FFPE tissues, we recommend using PD-L1 IHC panel ab236676, which contains PD-L1 antibody clone 28-8 (ab205921), HIER antigen retrieval reagent (ab208572) and IHC detection kit HRP/DAB (ab209101).

Western blot usage:
For clone 28-8, it is recommended to use Odyssey system. This system has the advantages of a wider dynamic range and less background than chemiluminescence.

This PD-L1 antibody [28-8] has been used as detector antibody in Human PD-L1 SimpleStep ELISA® kit: ab214565 and ab277712.

This product is a recombinant monoclonal antibody, which offers several advantages including:

  • – High batch-to-batch consistency and reproducibility
  • – Improved sensitivity and specificity
  • – Long-term security of supply
  • – Animal-free production
For more information see here.

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

Properties

Form

Liquid

Storage instructions

Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.

Storage buffer

pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol, 0.05% BSA
Concentration
  • Batch dependent within range: 50 µl at 0.994 – 1.095 mg/ml

Purity

Protein A purified

Clonality

Monoclonal

Clone number

28-8

Isotype

IgG

Research areas

  • Immunology
  •  
  • Cell Type Markers
  •  
  • CD
  •  
  • Non-lineage
  • Immunology
  •  
  • Immune System Diseases
  •  
  • Autoimmune
  • Cancer
  •  
  • Tumor immunology
  •  
  • Tumor-associated antigens
  • Cancer
  •  
  • Tumor biomarkers
  •  
  • Tumor antigens
  • Signal Transduction
  •  
  • Antibodies
  •  
  • pd-l1

Protocols